About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Pipeline
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Chronic Idiopathic Constipation
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
About Us
Our Mission & Values
Leadership Team
Board of Directors
Partners
Corporate Giving
Responsibility
Press Releases
Medicines
Science
Pipeline
Clinical Trials
Publications
Treatment Access
Patients & Caregivers
Our Commitment to Patients
Patient Voices
CKD with Hyperphosphatemia
IBS-C
Chronic Idiopathic Constipation
Join Us
Working at Ardelyx
Benefits
Open Positions
Medical Professionals
Investors & Media
Publications
Disease Area
Hyperphosphatemia
IBS-C
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Filter
The NHE3 Inhibitor Tenapanor Maintains Intestinal Barrier Function, Decreases Visceral Hypersensitivity, and Inhibits the TRPV1 Signaling in Colonic Sensory Neurons
American Journal of Physiology-Gastrointestinal and Liver Physiology
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study
Kidney360
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet
Kidney360
Tenapanor Improves Long-term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
Kidney360
Long-Term Safety of Tenapanor in Patients with Irritable Bowel Syndrome with Constipation in the T3MPO-3 Study
Neurogastroenterology & Motility
Pages:
1
2
3
4
5
6
7
8
9
Load More
Sorry, nothing found in this query